title: Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery.
abstract: Myocardial stunning after heart surgery is associated with increased morbidity and mortality in patients with severe multivessel disease and reduced myocardial function. The purpose of this study was to evaluate the safety, tolerance, and efficacy of adenosine as a cardioprotective agent when added to blood cardioplegia in patients undergoing coronary artery bypass surgery. Sixty-one patients were randomized to standard cold-blood cardioplegia, or cold-blood cardioplegia containing 1 of 5 adenosine doses (100 microM, 500 microM, 1 mM, 2 mM, and 2 mM with a preischemic infusion of 140 microg/kg/min of adenosine). Invasive and noninvasive measurements of ventricular performance and rhythm were obtained preoperatively, prebypass, and then at 1, 2, 4, 8, 16, and 24 hours postbypass. Use of inotropic agents and vasoactive drugs pastoperatively was recorded; blood samples were collected for measurement of nucleoside levels. High-dose adenosine treatment was associated with a 249-fold increase in the plasma adenosine concentration and a 69-fold increase in the combined levels of adenosine, inosine, and hypoxanthine (p <0.05). Increasing doses of the adenosine additive were also associated with lower requirements of dopamine (p = 0.003) and nitroglycerine (p = 0.001). The 24-hour average doses for dopamine and nitroglycerine in the placebo group were 28-fold and 2.6-fold greater than their respective high-dose adenosine treatment cohorts. Finally, the placebo- and 100 microM-adenosine group was associated with a lower ejection fraction when compared to patients receiving the intermediate dose or high-dose treatment. These findings are consistent with the hypothesis that adenosine is effective in attenuating myocardial stunning in humans.
authors.affiliation: University of Wisconsin, Department of Biostatistics, Milwaukee, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Mentzer
authors.forename: P S
authors.initials: PS
authors.lastname: Rahko
authors.forename: V
authors.initials: V
authors.lastname: Molina-Viamonte
authors.forename: C C
authors.initials: CC
authors.lastname: Canver
authors.forename: P S
authors.initials: PS
authors.lastname: Chopra
authors.forename: R B
authors.initials: RB
authors.lastname: Love
authors.forename: T D
authors.initials: TD
authors.lastname: Cook
authors.forename: J O
authors.initials: JO
authors.lastname: Hegge
authors.forename: R D
authors.initials: RD
authors.lastname: Lasley
mesh_terms: D000241:Adenosine / Q000008:administration & dosage* / Q000097:blood; D000293:Adolescent; D002314:Cardioplegic Solutions; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D001026:Coronary Artery Bypass / Q000379:methods*; D004298:Dopamine / Q000008:administration & dosage; D004361:Drug Tolerance; D004452:Echocardiography; D005260:Female; D006321:Heart / Q000503:physiopathology; D006801:Humans; D019271:Hypoxanthine / Q000097:blood; D007288:Inosine / Q000097:blood; D008297:Male; D017682:Myocardial Stunning / Q000188:drug therapy; D005996:Nitroglycerin / Q000008:administration & dosage; D012449:Safety; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D002314:Cardioplegic Solutions; D002317:Cardiovascular Agents; D014665:Vasodilator Agents; D019271:Hypoxanthine; D007288:Inosine; D005996:Nitroglycerin; D000241:Adenosine; D004298:Dopamine